Therapeutics that extend healthy human lifespan will redefine healthcare in the 21st century. Our primary investment focus is on early-stage companies developing therapies and technologies that target the root causes of aging. We also invest in platforms and technologies that aim to compress drug development timelines or increase accessibility to therapeutics within the context of extending healthy human lifespan. We are impact-driven and determined to fund the next great leaps in the field of healthspan science.